Published study proposes a better understanding of the site of inflammation in the diseaseCurrently there are no cures for rheumatoid arthritis (RA ...
Patients with PsA who received bimekizumab demonstrated sustained improvements in clinical outcomes for up to 52 weeks, regardless of concomitant MTX use.